Consensus. Chinese Consensus on Combination Therapy of Chronic Hepatitis B

Open access

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1 Niederau C Heintges T Lange S Goldmann G Niederau CM Mohr L et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.

  • 2 Liaw YF Sung JJ Chow WC Farrell G Lee CZ Yuen H et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.

  • 3 Di MV Marzano A Lampertico P Andreone P. Santantonio T. Almasio PL et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40: 883-891.

  • 4 Wang L Yan J Zhang Z Wang J Du Y Li X et al. Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy. C J Hepotol 2004;12:14-17.

  • 5 Zoulim F Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008;48 (Suppl 1):s2-s19.

  • 6 Lampertico P Vigano M Manenti E Iavarone M Sablon E Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445-1451.

  • 7 Yang YD Zheng L Jie HY. De novo lamivudine and adefovir dipivoxil combination therapy for patients with decompensated cirrhosis resulting from chronic hepatitis B. Hepatol Int 2010;4:134.

  • 8 Wan M. The present situation and pondering on antiviral therapy in patients with decompensated cirrhosis. C J Hepotol 2010;18:483-485.

  • 9 Lai CL Leung N Teo EK Tong M Wong F Hann HW et al. A 1-year trial of telbivudine lamivudine and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-536.

  • 10 Lok AS Trinh H Carosi G Akarca U Gadano A Habersetzer F et al. Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)idenaive patients with chronic hepatitis B (CHB): the BE-LOW study. 2011. AASLD.

  • 11 Keeffe EB Zeuzem S Koff RS Dieterich DT Esteban-Mur R Gane EJ et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-897.

  • 12 Chinese Roadmap Expert Group for Telbivudine Treatment. Chinese roadmap for treating chronic hepatitis B with telbivudine. C J Hepotol 2008;16:323-325.

  • 13 Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther 2009;14(1):13-22.

  • 14 Lai CL Gane E Liaw YF Hsu CW Thongsawat S Wang Y et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588.

  • 15 Lok AS McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.

  • 16 European Association For The Study Of The Live. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.

  • 17 Committee of experts on antiviral therapy of chronic hepatitis C. Experts consensus on antiviral therapy of chronic hepatitis C. C J Exp Clin Infect Dis (Electro Edi) 2009;3:343-352.

  • 18 Sherman M. Strategies for managing coinfection with hepatitis B virus and HIV. Cleve Clin J Med 2009;76(Suppl 3):S30-S33.

  • 19 Xie W Shi G Zhang H Zhao G Yu Z Lang Z et al. A randomized multi-central controlled study of patients with hepatitis B e antigenpositive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. Hepatol Int 2012;6:441-448.

  • 20 Qin G Shi G Song Y Chen M. Meta-analysis of document on diammonium Glycyrrhizinate in treatment of patients with chronic hepatitis B. C J Infect Dis 2005;23:333-337.

  • 21 Xia Y Liu J. Glycyrrhizin and derivatives for treatment of chronic hepatitis B:A systematic review of randomized controlled trials. C J Integr Tradit West Med Liver Dis 2007;17:304-309.

  • 22 Bao F Xie J. Combination therapy of milk thistles and interferon on hepatitis B. J Qiqihar Univer Med 2006;27:1185-1186.

  • 23 Gou W Wang Y. Combination therapy of milk thistles and interferon α-2b on hepatitis B. J Clin Hepatol 2004;20:302.

  • 24 Wong DK Cheung AM O’ Rourke K Naylor CD Detsky AS Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323.

  • 25 Harris JM Martin NE Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-551.

  • 26 Lau GK Piratvisuth T Luo KX Marcellin P Thongsawat S Cooksley G et al. Peginterferon Alfa-2a lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.

  • 27 Sarin SK Sood A Kumar M Arora A Amrapurkar D Sharma BC et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007;102:96-104.

  • 28 Chan HL Leung NW Hui AY Wong VW Liew CT Chim AM et al. A randomized controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha 2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-250.

  • 29 Wong VW Wong GL Yan KK Chim AM Chan HY Tse CH et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:1945-1953.

  • 30 Fried MW Piratvisuth T Lau GK Marcellin P Chow WC Cooksley G et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-434.

  • 31 Moucari R Mackiewicz V Lada O Ripault MP Castelnau C Martinot-Peignoux M et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-1157.

  • 32 Brunetto MR Moriconi F Bonino F Lau GK Farci P Yurdaydin C et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-1150.

  • 33 Wan M Wong X. Suggestion on chronic hepatitis B with interferon (2010). C J Infect Dis 2010;28:193-200.

  • 34 Vassiliadis T Tziomalos K Patsiaoura K Zagris T Giouleme O Soufleris K et al.Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. J Gastroenterol Hepatol 2007;22:1582-1588.

  • 35 Cao Z Zhang Y Ma L Sun G He Z Liu Y et al. Treatment of HBeAg-positive CHB infection with peginterferon alfa-2a [40KD] puls lamivudine or adefovir for 96 weeks resulting in high rate of HBsAg clearance seroconversion rates. 2010. AASLD.

  • 36 Zafar S Haque IU Rehman AU et al. Comparison of adefovir and standard interferon combination with standard interferon or adefovir for treatment of chronic hepatitis B. Pakistan J Gastroenterol 2009;23:9-15.

  • 37 Wursthorn K Lutgehetmann M Dandri M Volz T Buggisch P Zollner B et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-684.

  • 38 Ma W Zhou B Ao F Zhou D Hu Y He Q et al. Higher sustained post-treatment virologic response following peginterferon alfa-2a ± adefovir compared with adefovir monotherapy in HBeAg-positive patients. 2009. AASLD.

  • 39 Takkenberg B Zaaijer H Weegink C Terpstra V Dijkgraaf M Jansen1 P et al. Baseline HBsAg level predict HBsAg loss in CHB patients treated with a combination of peginterferon alfa-2a and adefovir: an interim analysis. 2009. EASL.

  • 40 Canada H. Risk of peripheral neuropathy in patients treated with telbivudine (SEBIVO) and interferon- For Health Professionals. (Accessed at

  • 41 European Medicines Agency. Risk of peripheral neuropathy with Sebivo (telbivudine). Media Release 2008;2:14.

  • 42 Liu M Yi W Cai H. Myositis and peripheral neuropathy associated with telbivudine and interferon. Adver Drug React J 2010;12:130-131.

  • 43 Baumann CA Badamchian M Goldstein AL. Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways. Mech Ageing Dev 1997;94:85-101.

  • 44 Loggi E Gramenzi A Margotti M Cursaro C Galli S Vitale G et al. In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B. J Viral Hepat 2008;15:442-448.

  • 45 Lim SG Wai CT Lee YM Dan YY Sutedja DS Wee A et al. A randomized placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther 2006;11:245-253.

  • 46 Mao H Shi T. Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a Meta-analysis. C J Hepatol 2011;19:29-33.

  • 47 Zhang Y Chen E Yang J Duan Y Tang H. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J 2009;6:63.

Journal information
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 152 80 10
PDF Downloads 73 47 8